Skip to main content

Ventilator-associated pneumonia in the era of COVID-19 pandemic: How common and what is the impact?

Abstract

We reviewed similarities and differences of ventilator associated pneumonia in Sars-Cov2 infection and with other ARDS. The differences in epidemiology and outcome will be detailed. Possible explanations of differences in pathophysiology of VAP in Sarscov2 infections will be cited and discussed.

Addressing the common issue of antimicrobial stewardship for bacterial superinfections in severe SARS-CoV-2 infections is particularly challenging, especially with the uncertainties about how to diagnose ventilator-associated pneumonia (VAP) and tracheobronchitis (VAT). As compared to other viral pneumonias, the reported incidence of community-acquired pulmonary bacterial coinfections with COVID-19 is as low as 3% and 5–16% for ward and Intensive Care Units (ICU) patients respectively [1, 2]. However, the frequency of VAP is uncertain, and its incidence, characteristics and prognosis remain to be further explored (Fig. 1).

Fig. 1
figure1

VAP risk in Sars-Cov2 infections and other ARDS: similarities and differences. The main elements of pathophysiology, diagnosis and treatment of VAP in ARDS patients are schematized in blue. In red, the potential elements due to sars-cov2 are discussed. MDR Multi-drug resistant; PDR pan-drug resistant; PK pharmacokinetic; mPCR multiplex PCR or other molecular methods

Significant disparities exist in the epidemiology of VAP, arguing for a standardization of definitions. Blonz et al., reported a crude incidence rate of 48.9% [1] in agreement with incidence rates ranging from 48 to 79% [3,4,5,6] in other cohorts. This rate contrasts substantially with the 29% observed in a multicenter study performed during the first COVID-19 wave in Italy [7]. In a retrospective study of 91 patients with COVID-19 respiratory failure (81 on a ventilator for > 48 h), Maes et al. reported a hazard ratio of 2.1, compared to non-COVID-19 patients, and an incidence of 79% with VAP [6]. In another study of 568 COVID-19 patients, 50.5% had either VAP or VAT, a higher incidence than was seen in influenza pneumonia or non-viral pneumonia [7]. It is clearly difficult to differentiate VAT from VAP in severe SARS-Cov-2 infections where modifications of chest radiographic infiltrates might be related to technical problems or intercurrent non-infectious events [8].

Additionally, VAP incidence may vary according to the bacteriological test used. Indeed, to avoid healthcare workers (HCW) contamination when the diagnosis of VAP is suspected, the use of bacteriological samples and bronchoscopy have been reduced, and gram stain examination not performed. The majority of VAPs were diagnosed based on bacteriological analysis from endotracheal aspirates (42.6%) in the study by Blonz et al., similar to the methods chosen by others [6]. Bronchoalveolar lavage (BAL) accounted for a quarter of sampling technique in COVID-ARDS patients, compared to 60% in non-COVID ARDS, in one study [3]. Importantly, quantitative distal as well as proximal samples were performed, but some authors only considered distal samples [3, 4], and others also included molecular methods [5, 9].

The increased risk of VAP in SARS-CoV-2 infections, as compared to other ARDS, may have been due to multiple factors including: less rigorous use of standard prevention strategies during COVID-19, disease and therapy-associated immune impairment, more prolonged duration of mechanical ventilation, prolonged use of sedation, more frequent need for prone ventilation, and higher risk for pulmonary infarction with associated superinfection. Although ICU overcrowding could also have been a factor, the study of Blonz et al. was done in an “uninundated” region where ICUs had adequate facilities for providing usual level of patient care, and thus there were less potential breaches in contact isolation. Similarly, in another single center study, a VAP rate reaching 74% was observed during both the first overcrowded wave and during the second wave where the ICU beds were sufficient [10].

SARS-CoV-2 ARDS patients have different clinical features than other ARDS patients, characterized by more profound hypoxia, and in comparative studies, the duration of mechanical ventilation was twice as long in COVID-19 patients compared with other types of ARDS [4, 5]. The extensive use of prone positioning could also have affected VAP incidence, and this therapy has been used in 67–83% of COVID-19 patients, generally twice as often as in influenza ARDS [3, 6]. Another difference with COVID-19 is the high risk of initial pulmonary emboli, which could predisposes to pulmonary infarction and secondary superinfections [11]. Immune alterations of the lung observed in ARDS patients [12] and COVID-19 patients, could be further amplified in SARS-CoV-2 infections by the use of corticosteroids or interleukin-receptor antagonists, as is suggested by some studies [13, 14], but not confirmed by recent randomized controlled trials [15].

VAP complicating SARS-CoV-2 infections occurred often late during mechanical ventilation [1, 4, 5]. Pathogens recovered are dependent on the local epidemiology. Enterobacterales accounted for two thirds of VAP (mainly Escherichia coli and Klebsiella pneumoniae), with half of these organisms being resistant to 3rd-generation cephalosporins. Notably, a significantly higher rate of Extended Spectrum Beta-lactamase-producing Enterobacterales (ESBL-PE) have been reported, compared to historical non-COVID-19 controls (72% vs 47%), and Aspergillus appears more common in COVID-19 respiratory failure than in other populations [3]. Interestingly, bloodstream infections (BSI) occurred in 10.6% of cases while pneumonia represented 21% of the source of BSI. Although prior antibiotic therapy can generally predispose to resistant organisms, Blonz et al. found that initial empiric therapy seemed to reduce the risk of polymicrobial VAP [1].

Finally some studies found an important rate of complicated VAP with lung abscesses and empyema [1] Substantial perfusion defects and impaired antibiotic diffusion into the parenchyma, could reasonably explain these failures, due to insufficient antibiotic concentration in the lung. We think that close therapeutic drug monitoring should be used in these patients with augmented renal clearance, to prevent therapeutic failures [12]. Given the high risk of pulmonary superinfections, and antibiotic failure, considerable effort to promote and implement prevention policies are of key importance especially in case of pandemic and healthcare system overcrowding. In this particular situation, even if MDR bacteria colonization is frequent, selective digestive or oral decontamination, or early intravenous antibiotic prophylaxis might be tested.

Availability of data and materials

Not applicable.

Abbreviations

ICU:

intensive care units

VAP:

ventilation-associated pneumonia

ARDS:

acute respiratory distress syndrome

VAT:

ventilation-associated tracheobronchitis

HCW:

health care workers

BAL:

bronchoalveolar lavage

ESBL-PE:

extended spectrum beta-lactamase producing enterobacterales

BSI:

blood stream infections

MDR:

multidrug resistant

PDR:

pan-drug resistant

PK:

pharmacokinetic

mPCR:

multiplex PCR or other molecular methods

References

  1. 1.

    Blonz G, Kouatchet A, Chudeau N, Pontis E, Lorber J, Lemeur A, et al. Epidemiology and microbiology of ventilator-associated pneumonia in COVID-19 patients: a multicenter retrospective study in 188 patients in an un-inundated French region. Crit Care. 2021;25:6–12.

    Article  Google Scholar 

  2. 2.

    Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27(1):83–8.

    CAS  Article  Google Scholar 

  3. 3.

    Razazi K, Arrestier R, Haudebourg AF, Benelli B, Carteaux G, Decousser J-W, et al. Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease. Crit Care. 2020;24(1):699.

    Article  Google Scholar 

  4. 4.

    Luyt C-E, Sahnoun T, Gautier M, Vidal P, Burrel S, de Chambrun MP, et al. Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study. Ann Intensive Care. 2020;10(1):158.

    Article  Google Scholar 

  5. 5.

    Maes M, Higginson E, Pereira-Dias J, Curran MD, Parmar S, Khokhar F, et al. Ventilator-associated pneumonia in critically ill patients with COVID-19. Crit Care. 2021;25(1):25.

    Article  Google Scholar 

  6. 6.

    Rouzé A, Martin-Loeches I, Povoa P, Makris D, Artigas A, Bouchereau M, et al. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med. 2021;2:188–98.

    Article  Google Scholar 

  7. 7.

    Giacobbe DR, Battaglini D, Enrile EM, Dentone C, Vena A, Robba C, et al. Incidence and prognosis of ventilator-associated pneumonia pneumonia in critically ill patients with COVID-19: a multicenter study. J Clin Med. 2021;10(4):555.

    Article  Google Scholar 

  8. 8.

    Nair GB, Niederman MS. Ventilator-associated pneumonia: present understanding and ongoing debates. Intensive Care Med. 2015;41(1):34–48.

    Article  Google Scholar 

  9. 9.

    Maataoui N, Chemali L, Patrier J, Tran Dinh A, Le Fèvre L, Lortat-Jacob B, et al. Impact of rapid multiplex PCR on management of antibiotic therapy in COVID-19-positive patients hospitalized in intensive care unit. Eur J Clin Microbiol Infect Dis. 2021;17:1–8.

    Google Scholar 

  10. 10.

    Contou D, Cally R, Sarfati F, Desaint P, Fraissé M, Plantefève G. Causes and timing of death in critically ill COVID-19 patients. Crit Care. 2021;25(1):79.

    Article  Google Scholar 

  11. 11.

    Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;6:1089–98.

    Article  Google Scholar 

  12. 12.

    Luyt C-E, Bouadma L, Morris AC, Dhanani JA, Kollef M, Lipman J, et al. Pulmonary infections complicating ARDS. Intensive Care Med. 2020;46(12):2168–83.

    Article  Google Scholar 

  13. 13.

    Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa954.

    Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Buetti N, Ruckly S, de Montmollin E, Reignier J, Terzi N, Cohen Y, et al. COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network. Intensive Care Med. 2021;47(2):180–7.

    CAS  Article  Google Scholar 

  15. 15.

    Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv [Internet]. [cited 2021 Mar 16]. Available from: https://doi.org/10.1101/2021.02.11.21249258v1

Download references

Funding

JFT was supported by the Innovative Medicines Initiative Joint Undertaking (Grant No. 115523) [Combatting Bacterial Resistance in Europe], resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2020) and European Federation of Pharmaceutical Industries and Associations companies’ in-kind contributions.

Author information

Affiliations

Authors

Contributions

PHW, MN and JFT: Conception and writing. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jean-François Timsit.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

JFT declares advisory board participation for Pfizer, Merck, Bayer pharma, Shionoghi, Medimune, Paratek, Gilead, Beckton-Dickinson, lecture fees from Merck, Biomerieux, Pfizer and Grants to his research group from Pfizer, Merck, Thermofisher all outside the submitted work. The other authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wicky, PH., Niedermann, M.S. & Timsit, JF. Ventilator-associated pneumonia in the era of COVID-19 pandemic: How common and what is the impact?. Crit Care 25, 153 (2021). https://doi.org/10.1186/s13054-021-03571-z

Download citation

Keywords

  • COVID-19
  • ARDS
  • Ventilation-associated pneumonia
  • Superinfections
  • Prognostic
\